血清 miR-21 可预测原发性胃肠道弥漫大 B 细胞淋巴瘤患者的预后。

Serum miR-21 predicts the prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma.

机构信息

Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi, China.

Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

出版信息

Acta Biochim Pol. 2022 Jun 12;69(2):379-385. doi: 10.18388/abp.2020_5816.

DOI:10.18388/abp.2020_5816

PMID:35691029

Abstract

BACKGROUND

Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) lacks specific clinical manifestations and its malignancy renders prognostication and choice of treatment strategy difficult. The aim of this study was to evaluate microRNA (miR)-21 as potential non-invasive biomarkers for prognosis in PGI-DLBCL patients.

METHODS

Serum miR-21 expression in de novo PGI-DLBCL patients, consecutively enrolled for this study, was detected by quantitative real-time polymerase chain reaction (qRT-PCR). Relative expression was calculated using the comparative Ct method. Statistical significance was determined using the Mann-Whitney rank sum and Fisher's exact test. Survival analysis was conducted using the Kaplan-Meier method.

RESULTS

Compared with healthy controls, serum miR-21 levels were significantly elevated in the PGI-DLBCL patients (n=156). The high expression level of serum miR-21 at diagnosis was associated with worse progression-free survival (PFS) (30 (9-42) vs 42 (12-52) months in high and low miR-21 groups) and overall survival (OS) (35 (15-52) vs 48 (17-61) months in high and low miR-21 groups) and was an independent risk factor for PFS and OS (hazard ratios 4.345 and 3.311, respectively). Furthermore, Bcl-2, Bcl-6 and Ki-67 were independently and positively associated with miR-21 expression.

CONCLUSIONS

Our results suggest that miR-21 is a potential prognostic marker to predict clinical outcomes in PGI-DLBCL patients and a high miR-21 level is associated with poor outcomes.

摘要

背景

原发性胃肠道弥漫大 B 细胞淋巴瘤（PGI-DLBCL）缺乏特异性临床表现，其恶性程度使得预后和治疗策略的选择变得困难。本研究旨在评估 microRNA（miR）-21 是否可作为 PGI-DLBCL 患者预后的潜在非侵入性生物标志物。

方法

采用实时定量聚合酶链反应（qRT-PCR）检测本研究连续纳入的初治 PGI-DLBCL 患者血清 miR-21 表达。采用比较 Ct 法计算相对表达量。采用 Mann-Whitney 秩和检验和 Fisher 确切检验确定统计学意义。采用 Kaplan-Meier 法进行生存分析。

结果

与健康对照者相比，PGI-DLBCL 患者血清 miR-21 水平显著升高（n=156）。诊断时血清 miR-21 高表达与无进展生存期（PFS）（高 miR-21 组 30（9-42）个月 vs 低 miR-21 组 42（12-52）个月）和总生存期（OS）（高 miR-21 组 35（15-52）个月 vs 低 miR-21 组 48（17-61）个月）较差相关，是 PFS 和 OS 的独立危险因素（危险比分别为 4.345 和 3.311）。此外，Bcl-2、Bcl-6 和 Ki-67 与 miR-21 表达独立且呈正相关。